Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF 52 WEEKS OF ONCE DAILY TREATMENT OF ORALLY INHALED TIOTROPIUM + OLODATEROL FIXED DOSE COMBINATION COMPARED WITH TIOTROPIUM ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) EXACERBATION IN PATIENTS WITH SEVERE TO VERY SEVERE COPD

Intervention/treatment:
OLODATEROL (BI 1744)-TIOTROPIUM
Medical condition:
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Protocol code:
1237.19
Control number:
179154
Status:
Closed
Approved:
November 18, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02296138
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Boehringer Ingelheim, Call Center
Organization
Boehringer Ingelheim
Phone:
1-800-243-0127
Sponsor
BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Locations

Alberta

1237.19.20011 Boehringer Ingelheim Investigational Site
Calgary, Alberta
1237.19.20016 Boehringer Ingelheim Investigational Site
Edmonton, Alberta
1237.19.20020 Boehringer Ingelheim Investigational Site
Calgary, Alberta
1237.19.20025 Boehringer Ingelheim Investigational Site
Edmonton, Alberta

British Columbia

1237.19.20010 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia
1237.19.20033 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia
1237.19.20034 Boehringer Ingelheim Investigational Site
Kelowna, British Columbia
1237.19.20035 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia
1237.19.20036 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia
1237.19.20041 Boehringer Ingelheim Investigational Site
Maple Ridge, British Columbia

Manitoba

1237.19.20015 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba

New Brunswick

1237.19.20006 Boehringer Ingelheim Investigational Site
Saint John, New Brunswick
1237.19.20021 Boehringer Ingelheim Investigational Site
Moncton, New Brunswick

Newfoundland and Labrador

1237.19.20013 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador

Ontario

1237.19.20005 Boehringer Ingelheim Investigational Site
Toronto, Ontario
1237.19.20007 Boehringer Ingelheim Investigational Site
Windsor, Ontario
1237.19.20009 Boehringer Ingelheim Investigational Site
Courtice, Ontario
1237.19.20012 Boehringer Ingelheim Investigational Site
Waterloo, Ontario
1237.19.20017 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1237.19.20018 Boehringer Ingelheim Investigational Site
Burlington, Ontario
1237.19.20019 Boehringer Ingelheim Investigational Site
Grimsby, Ontario
1237.19.20022 Boehringer Ingelheim Investigational Site
London, Ontario
1237.19.20026 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1237.19.20029 Boehringer Ingelheim Investigational Site
Corunna, Ontario
1237.19.20030 Boehringer Ingelheim Investigational Site
Sarnia, Ontario
1237.19.20037 Boehringer Ingelheim Investigational Site
Toronto, Ontario
1237.19.20038 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1237.19.20040 Boehringer Ingelheim Investigational Site
Ottawa, Ontario

Quebec

1237.19.20003 Boehringer Ingelheim Investigational Site
Victoriaville, Quebec
1237.19.20004 Boehringer Ingelheim Investigational Site
Longueuil, Quebec
1237.19.20008 Boehringer Ingelheim Investigational Site
Point Claire, Quebec
1237.19.20014 Boehringer Ingelheim Investigational Site
Québec, Quebec
1237.19.20023 Boehringer Ingelheim Investigational Site
Ste-Foy, Quebec
1237.19.20031 Boehringer Ingelheim Investigational Site
Saint-Charles-Borromée, Quebec
1237.19.20032 Boehringer Ingelheim Investigational Site
Montreal, Quebec
1237.19.20039 Boehringer Ingelheim Investigational Site
Trois-Rivières, Quebec

Saskatchewan

1237.19.20002 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan
1237.19.20027 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan

Results

See the results from the trial NCT02296138. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?